



## OPEN ACCESS

EDITED AND REVIEWED BY  
Arianna Maffei,  
Stony Brook University, United States

## \*CORRESPONDENCE

Deusedit Tusubira  
✉ dtusubira@must.ac.ug  
Kehinde Ross  
✉ o.k.ross@ljmu.ac.uk

## SPECIALTY SECTION

This article was submitted to  
Cellular Neurophysiology,  
a section of the journal  
Frontiers in Cellular Neuroscience

RECEIVED 26 November 2022

ACCEPTED 02 December 2022

PUBLISHED 16 December 2022

## CITATION

Sekar D, Tusubira D and Ross K (2022)  
Corrigendum: TDP-43 and NEAT long  
non-coding RNA: Roles in  
neurodegenerative disease.  
*Front. Cell. Neurosci.* 16:1108593.  
doi: 10.3389/fncel.2022.1108593

## COPYRIGHT

© 2022 Sekar, Tusubira and Ross. This  
is an open-access article distributed  
under the terms of the [Creative  
Commons Attribution License \(CC BY\)](#).  
The use, distribution or reproduction  
in other forums is permitted, provided  
the original author(s) and the copyright  
owner(s) are credited and that the  
original publication in this journal is  
cited, in accordance with accepted  
academic practice. No use, distribution  
or reproduction is permitted which  
does not comply with these terms.

# Corrigendum: TDP-43 and NEAT long non-coding RNA: Roles in neurodegenerative disease

Durairaj Sekar<sup>1</sup>, Deusedit Tusubira <sup>2\*</sup> and  
Kehinde Ross <sup>3,4\*</sup>

<sup>1</sup>Centre for Cellular and Molecular Research, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, India,

<sup>2</sup>Department of Biochemistry, Mbarara University of Science and Technology, Mbarara, Uganda,

<sup>3</sup>School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, United Kingdom, <sup>4</sup>Institute for Health Research, Liverpool John Moores University, Liverpool, United Kingdom

## KEYWORDS

TDP-43, long non-coding RNA, NEAT1, neurons, paraspeckles, TAR DNA-binding protein 43, nucleic acid therapies, swimming microrobots

## A corrigendum on

## TDP-43 and NEAT long non-coding RNA: Roles in neurodegenerative disease

by Sekar, D., Tusubira, D., and Ross, K. (2022). *Front. Cell. Neurosci.* 16:954912.  
doi: 10.3389/fncel.2022.954912

In the published article, there was an error. Messenger RNA was spelt out as “messenger ribosomal nucleic acid” instead of “messenger ribonucleic acid.” A correction has been made to the **Abstract**. The corrected abstract is below.

“Understanding and ameliorating neurodegenerative diseases represents a key challenge for supporting the health span of the aging population. Diverse protein aggregates have been implicated in such neurodegenerative disorders, including amyloid- $\beta$ ,  $\alpha$ -synuclein, tau, fused in sarcoma (FUS), and transactivation response element (TAR) DNA-binding protein 43 (TDP-43). Recent years have seen significant growth in our mechanistic knowledge of relationships between these proteins and some of the membrane-less nuclear structures that fulfill key roles in the cell function. These include the nucleolus, nuclear speckles, and paraspeckles. The ability of macromolecular protein:RNA complexes to partition these nuclear condensates through biophysical processes that involve liquid–liquid phase separation (LLPS) has also gained attention recently. The paraspeckle, which is scaffolded by the architectural long-non-coding RNA nuclear enriched abundant transcript 1 (NEAT1) plays central roles in RNA processing and metabolism and has been linked dynamically to TDP-43. In this mini-review, we outline essential early and recent insights in relation to TDP-43 proteinopathies. We then appraise the relationships between TDP-43 and NEAT1 in the context of neuronal paraspeckles and neuronal stress. We highlight key areas for investigation based on recent advances in our understanding of how TDP-43 affects neuronal function, especially in relation to messenger ribonucleic acid (mRNA) splicing. Finally, we offer

perspectives that should be considered for translational pipelines in order to improve health outcomes for the management of neurodegenerative diseases.”

In the published article, there was an error. Messenger RNA was spelt out as “messenger ribosomal nucleic acid” instead of “messenger ribonucleic acid.” A correction has been made to the **Introduction**, paragraph 4. The corrected paragraph is below.

“Transactivation response element (TAR) DNA-binding protein 43 is a highly conserved heterogeneous ribonucleoprotein (hnRNP) multi-domain protein first identified as a 43-kDa protein that bound the TAR in human immunodeficiency virus (Ou et al., 1995). Under normal physiological conditions, TDP-43 is subjected to nucleocytoplasmic shuttling while residing predominantly in the nucleus (Ayala et al., 2008). This localization to both nuclear and cytosolic compartments is reflected in the processes regulated by TDP-43, which span messenger ribonucleic acid (mRNA) transcription splicing, maturation, and mRNA transport as well as the formation of stress granules and the regulation of miRNA processing, as reviewed recently by Prasad et al. (2019). Unsurprisingly, therefore, mutations that increase TDP-43 aggregation, increase TDP-43 half-life, or alter TDP-43 interactions with other proteins are thought to contribute

to disease pathology in TDP-43 proteinopathies, and over 52 TDP-43 mutations have been linked to disease (Buratti, 2015).”

In the published article, there was an error. Messenger RNA was spelt out as “messenger ribosomal nucleic acid” instead of “messenger ribonucleic acid.” A correction has been made to the section heading “**Therapeutic horizons: Inspiration from COVID-19 messenger ribosomal nucleic acid vaccines.**” The corrected heading is “**Therapeutic horizons: Inspiration from COVID-19 messenger ribonucleic acid vaccines.**”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## References

- Ayala, Y. M., Zago, P., D’Ambrogio, A., Xu, Y. F., Petrucelli, L., Buratti, E., et al. (2008). Structural determinants of the cellular localization and shuttling of TDP-43. *J. Cell Sci.* 121, 3778–3785. doi: 10.1242/jcs.038950
- Buratti, E. (2015). Functional Significance of TDP-43 Mutations in Disease. *Adv. Genet.* 91, 1–53. doi: 10.1016/bs.adgen.2015.07.001
- Ou, S. H., Wu, F., Harrich, D., Garcia-Martinez, L. F., and Gaynor, R. B. (1995). Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. *J. Virol.* 69, 3584–3596. doi: 10.1128/jvi.69.6.3584-3596.1995
- Prasad, A., Bharathi, V., Sivalingam, V., Girdhar, A., and Patel, B. K. (2019). Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. *Front. Mol. Neurosci.* 12:25. doi: 10.3389/fnmol.2019.00025